The European Medicines Agency (EMA) has agreed to review an application submitted by Sanofi for the use of Dupixent (dupilumab) to treat inadequately controlled moderate-to-severe asthma.

Dupixent is a human monoclonal antibody developed to block interleukin-4 (IL-4) and interleukin-13 (IL-13) signalling associated with type 2 inflammation.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug is currently approved in the EU and the US to treat moderate-to-severe atopic dermatitis in adults.

The latest application seeks approval as an add-on maintenance treatment of some asthma patients aged 12 and above.

It includes results from three pivotal trials involving 2,888 subjects under the Liberty Asthma clinical development programme.

“The latest application seeks approval as an add-on maintenance treatment of some asthma patients aged 12 years and above.”

Sanofi and Regeneron are also evaluating dupilumab in different development programmes for type 2 inflammatory conditions such as paediatric atopic dermatitis, nasal polyps and eosinophilic esophagitis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The drug’s supplemental biologics license application (sBLA) is under review by the US Food and Drug Administration (FDA) as an add-on maintenance therapy in select adults and adolescents with moderate-to-severe asthma.

The European regulatory authority has accepted Sanofi’s marketing authorisation application (MAA) for cemiplimab to treat metastatic cutaneous squamous cell carcinoma (CSCC) for review.

Cemiplimab is a human monoclonal antibody being developed by Sanofi and Regeneron to target the programmed cell death protein-1 (PD-1) checkpoint inhibitor.

The MAA is supported by findings from a pivotal, single-arm, open-label Phase II trial and data from two other Phase I expansion cohorts involving advanced metastatic and locally advanced CSCC patients not eligible for surgery.